Pharmacological effect of gelsemine on anxiety-like behavior in rat

Behavioural Brain Research

Volumn 253, Issue , 2013, Pages 90-94

  Meyer, Laurence ^a   Boujedaini, Naoual ^b   Patte Mensah, Christine ^a   Mensah Nyagan, Ayikoe G ^a  

^a UNIVERSITÉ DE STRASBOURG   (France)

^b Laboratoires Boiron   (France)

Author keywords

Anxiety; Elevated plus maze; Gelsemine; Gelsemium; Therapeutic strategy

Indexed keywords

ANXIOLYTIC AGENT; DIAZEPAM; GELSEMINE; UNCLASSIFIED DRUG;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANXIETY DISORDER; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; LIMBIC SYSTEM; LOW DRUG DOSE; MALE; NONHUMAN; PRIORITY JOURNAL; PSYCHOLOGIC ASSESSMENT; RAT; TRANQUILIZING ACTIVITY;

ANXIETY; ELEVATED PLUS-MAZE; GELSEMINE; GELSEMIUM; THERAPEUTIC STRATEGY;

ALKALOIDS; ANIMALS; ANTI-ANXIETY AGENTS; ANXIETY; BEHAVIOR, ANIMAL; DIAZEPAM; DOSE-RESPONSE RELATIONSHIP, DRUG; EXPLORATORY BEHAVIOR; GELSEMIUM; INJECTIONS, INTRAPERITONEAL; MALE; MAZE LEARNING; MOTOR ACTIVITY; RATS; RATS, SPRAGUE-DAWLEY;

EID: 84880938127     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2013.07.010     Document Type: Article

References (34)

1. Grecian S., Aube J. Double conjugate addition of a nitropropionate ester to a quinone monoketal: synthesis of an advanced intermediate to (+/-)-gelsemine. Organic Letters 2007, 9:3153-3156.
2. Madin A., O'Donnell C.J., Oh T., Old D.W., Overman L.E., Sharp M.J. Total synthesis of (+/-)-gelsemine. Angewandte Chemie International Edition 1999, 38:2934-2936.
3. Ng F.W., Lin H., Chiu P., Danishefsky S.J. Explorations in organic chemistry leading to the total synthesis of (+/-)-gelsemine. Journal of the American Chemical Society 2002, 124:9812-9824.
4. Ozturk C., Aviyente V., Houk K.N. Modeling the stereoselectivity of the Johnson-Claisen rearrangements in the Danishefsky synthesis of gelsemine. Journal of Organic Chemistry 2005, 70:7028-7034.
5. Yokoshima S., Tokuyama H., Fukuyama T. Enantioselective total synthesis of (+)-gelsemine: determination of its absolute configuration. Angewandte Chemie International Edition 2000, 39:4073-4075.
6. Bousta D., Soulimani R., Jarmouni I., Belon P., Falla J., Froment N., et al. Neurotropic, immunological and gastric effects of low doses of Atropa belladonna L., Gelsemium sempervirens L. and Poumon histamine in stressed mice. Journal of Ethnopharmacology 2001, 74:205-215.
7. Peredery O., Persinger M.A. Herbal treatment following post-seizure induction in rat by lithium pilocarpine: Scutellaria lateriflora (Skullcap), Gelsemium sempervirens (Gelsemium) and Datura stramonium (Jimson Weed) may prevent development of spontaneous seizures. Phytotherapy Research 2004, 18:700-705.
8. Bellavite P., Magnani P., Zanolin E., Conforti A. Homeopathic doses of gelsemium sempervirens improve the behavior of mice in response to novel environments. Evidence-Based Complementary and Alternative Medicine 2011, 10.1093/ecam/nep1139.
9. Magnani P., Conforti A., Zanolin E., Marzotto M., Bellavite P. Dose-effect study of Gelsemium sempervirens in high dilutions on anxiety-related responses in mice. Psychopharmacology 2010, 210:533-545.
10. Liu M., Huang H.H., Yang J., Su Y.P., Lin H.W., Lin L.Q., et al. The active alkaloids of Gelsemium elegans Benth. are potent anxiolytics. Psychopharmacology 2013, 225:839-851.
11. Chirumbolo S. Gelsemine and Gelsemium sempervirens L. Extracts in animal behavioral test: comments and related biases. Frontiers in Neurology 2011, 2:31.
12. Rammal H., Soulimani R. Effects of high doses of Gelsemium Sempervirens L. on GABA receptor and on the cellular and humoral immunity in mice. Journal of Medicine and Medical Sciences 2010, 1:40-44.
13. Lal H., Prather P.L., Rezazadeh S.M. Anxiogenic behavior in rats during acute and protracted ethanol withdrawal: reversal by buspirone. Alcohol 1991, 8:467-471.
14. Pellow S., Chopin P., File S.E., Briley M. Validation of open:closed arm entries in an elevated plus-maze as a measure of anxiety in the rat. Journal of Neuroscience Methods 1985, 14:149-167.
15. Rodgers R.J., Dalvi A. Anxiety, defence and the elevated plus-maze. Neuroscience & Biobehavioral Reviews 1997, 21:801-810.
16. Walf A.A., Frye C.A. The use of the elevated plus maze as an assay of anxiety-related behavior in rodents. Nature Protocols 2007, 2:322-328.
17. Carobrez A.P., Bertoglio L.J. Ethological and temporal analyses of anxiety-like behavior: the elevated plus-maze model 20 years on. Neuroscience & Biobehavioral Reviews 2005, 29:1193-1205.
18. Dawson G.R., Tricklebank M.D. Use of the elevated plus maze in the search for novel anxiolytic agents. Trends in Pharmacological Sciences 1995, 16:33-36.
19. Ramos A. Animal models of anxiety: do I need multiple tests. Trends in Pharmacological Sciences 2008, 29:493-498.
20. Woods J.H., Katz J.L., Winger G. Benzodiazepines: use, abuse, and consequences. Pharmacological Reviews 1992, 44:151-347.
21. Kent J.M., Mathew S.J., Gorman J.M. Molecular targets in the treatment of anxiety. Biological Psychiatry 2002, 52:1008-1030.
22. Fernandez Espejo E. Structure of the mouse behaviour on the elevated plus-maze test of anxiety. Behavioural Brain Research 1997, 86:105-112.
23. Cruz A.P., Frei F., Graeff F.G. Ethopharmacological analysis of rat behavior on the elevated plus-maze. Pharmacology Biochemistry and Behavior 1994, 49:171-176.
24. Venard C., Boujedaini N., Belon P., Mensah-Nyagan A.G., Patte-Mensah C. Regulation of neurosteroid allopregnanolone biosynthesis in the rat spinal cord by glycine and the alkaloidal analogs strychnine and gelsemine. Neuroscience 2008, 153:154-161.
25. Venard C., Boujedaini N., Mensah-Nyagan A.G., Patte-Mensah C. Comparative analysis of gelsemine and gelsemium sempervirens activity on neurosteroid allopregnanolone formation in the spinal cord and limbic system. Evidence-Based Complementary and Alternative Medicine 2011, 10.1093/ecam/nep1083.
26. Bannerman D.M., Rawlins J.N., McHugh S.B., Deacon R.M., Yee B.K., Bast T., et al. Regional dissociations within the hippocampus - memory and anxiety. Neuroscience & Biobehavioral Reviews 2004, 28:273-283.
27. Bremner J.D. Alterations in brain structure and function associated with post-traumatic stress disorder. Seminars in Clinical Neuropsychiatry 1999, 4:249-255.
28. Davis M. The role of the amygdala in fear and anxiety. Annual Review of Neuroscience 1992, 15:353-375.
29. Rauch S.L., Shin L.M., Wright C.I. Neuroimaging studies of amygdala function in anxiety disorders. Annals of the New York Academy of Sciences 2003, 985:389-410.
30. Akwa Y., Purdy R.H., Koob G.F., Britton K.T. The amygdala mediates the anxiolytic-like effect of the neurosteroid allopregnanolone in rat. Behavioural Brain Research 1999, 106:119-125.
31. Belelli D., Lambert J.J. Neurosteroids: endogenous regulators of the GABA(A) receptor. Nature Reviews Neuroscience 2005, 6:565-575.
32. Bitran D., Purdy R.H., Kellogg C.K. Anxiolytic effect of progesterone is associated with increases in cortical allopregnanolone and GABAA receptor function. Pharmacology Biochemistry and Behavior 1993, 45:423-428.
33. Rupprecht R., Rammes G., Eser D., Baghai T.C., Schule C., Nothdurfter C., et al. Translocator protein (18kD) as target for anxiolytics without benzodiazepine-like side effects. Science 2009, 325:490-493.
34. Rupprecht R., Papadopoulos V., Rammes G., Baghai T.C., Fan J., Akula N., et al. Translocator protein (18kDa) (TSPO) as a therapeutic target for neurological and psychiatric disorders. Nature Reviews Drug Discovery 2010, 9:971-988.